Cargando…
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing pro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290897/ https://www.ncbi.nlm.nih.gov/pubmed/37369262 http://dx.doi.org/10.1016/j.addr.2023.114973 |
_version_ | 1785062585648807936 |
---|---|
author | Han, Geonhee Noh, Dahye Lee, Hokyung Lee, Sangmin Kim, Sehoon Yoon, Hong Yeol Lee, Soo Hyeon |
author_facet | Han, Geonhee Noh, Dahye Lee, Hokyung Lee, Sangmin Kim, Sehoon Yoon, Hong Yeol Lee, Soo Hyeon |
author_sort | Han, Geonhee |
collection | PubMed |
description | RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality. |
format | Online Article Text |
id | pubmed-10290897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102908972023-06-26 Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery Han, Geonhee Noh, Dahye Lee, Hokyung Lee, Sangmin Kim, Sehoon Yoon, Hong Yeol Lee, Soo Hyeon Adv Drug Deliv Rev Article RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality. Elsevier B.V. 2023-08 2023-06-25 /pmc/articles/PMC10290897/ /pubmed/37369262 http://dx.doi.org/10.1016/j.addr.2023.114973 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Han, Geonhee Noh, Dahye Lee, Hokyung Lee, Sangmin Kim, Sehoon Yoon, Hong Yeol Lee, Soo Hyeon Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title | Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title_full | Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title_fullStr | Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title_full_unstemmed | Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title_short | Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery |
title_sort | advances in mrna therapeutics for cancer immunotherapy: from modification to delivery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290897/ https://www.ncbi.nlm.nih.gov/pubmed/37369262 http://dx.doi.org/10.1016/j.addr.2023.114973 |
work_keys_str_mv | AT hangeonhee advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT nohdahye advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT leehokyung advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT leesangmin advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT kimsehoon advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT yoonhongyeol advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery AT leesoohyeon advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery |